Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bilcare establishes new global headquarters in San Francisco
The headquarters, which will be led by CEO Vito Mangiardi, operates as the company’s corporate hub to drive growth in Bilcare’s American, European, and Asian regions. Dr Mangiardi
The headquarters, which will be led by CEO Vito Mangiardi, operates as the company’s corporate hub to drive growth in Bilcare’s American, European, and Asian regions. Dr Mangiardi
The data indicate that PYY did not meet the primary efficacy endpoint of a dose response of weight loss versus PYY dose, nor did PYY meet the secondary
Robin Smith, chairman and CEO of NeoStem, said: “Securing the Santa Monica site for a new collection center in our network is an important step for us as
The Israeli Ministry of Health will finance the entire project, including the development, planning and production of the snakebite antiserum and the establishment of an antiserum manufacturing facility.
Labopharm’s marketing partner for South Korea, WhanIn Pharmaceutical launched the product under the brand name TramaConti CR and its marketing partner for Australia, iNova Pharmaceuticals, launched the product
This multi-center, randomized, double-blind, vehicle-controlled, parallel group study was designed to assess the safety and preliminary efficacy of two dose levels of topical PTH (1-34) for the treatment
The patent office issued a ‘notice of allowance’ for patent application, which covers stabilized, small interfering RNA (siRNA) molecules with defined positional modifications. The claims cover siRNA molecules
Andes, an international, double-blind trial, showed a dose-dependent, statistically significant drop in glycosylated hemoglobin (A1c) of 0.6% and 0.4% in the 150mg and 75mg arms, respectively, at six
Bristol-Myers Squibb currently owns approximately 17% of all outstanding shares of ImClone. Bristol-Myers Squibb’s all-cash offer, which is not conditioned on the receipt of financing or on the
Based upon available information, Handa believes that it is the first applicant to file an abbreviated new drug application (ANDA) for Seroquel XR containing a paragraph IV certification,